Navigation Links
Cancer risk found for long-term hormone therapy
Date:8/11/2010

Using postmenopausal hormone therapy for more than 15 years increases a woman's risk of developing breast cancer, particularly among leaner women according to research at the Keck School of Medicine of the University of Southern California (USC).

An analysis of the California Teachers Study focused on postmenopausal hormone therapy use among more than 55,000 women for nearly 10 years. The research was conducted by a team including first author Tanmai Saxena, an M.D. Ph.D student at the Keck School. The research was published today in Cancer Epidemiology, Biomarkers and Prevention, an American Association for Cancer Research journal.

Compared with women who never used postmenopausal hormone therapy, women who used estrogen therapy for more than 15 years were at a 19 percent increased risk of breast cancer. The risk was even more pronounced for women who used combined therapy with estrogen plus progestin for 15 or more years. These women had an increased risk of 83 percent, Saxena said.

"This study shows that there needs to be a personalized conversation with women about the risks of using postmenopausal hormone therapy," said Saxena. "Different women appear to have different risks from hormones."

Thinner women who go on hormone therapy also appear to be at higher risk, Saxena said.

The research revealed that body mass index (BMI) may be an indicator of breast cancer risk for women who use postmenopausal hormone therapy. Women with a BMI of 30 or less appear to be at increased risk of breast cancer from combined therapy, while women with a BMI of 30 or higher were at less risk. Women with a BMI of 25 or less were at the highest risk.

The purpose of the study was to elaborate on the Women's Health Initiative findings regarding the effects of postmenopausal hormone therapy on breast cancer risk. The 15-year WHI, conducted by the National Institutes of Health, was halted in 2002 after increased risks of cardiovascular disease and breast cancer were found among women who were taking combination therapy as part of the trial. This study looked at the risk associated with particular formulations of combination hormone therapy as well as the subtypes of breast cancer resulting.


'/>"/>

Contact: Leslie Ridgeway
leslie.ridgeway@usc.edu
323-442-2823
University of Southern California
Source:Eurekalert

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
3. The dietary supplement genistein can undermine breast cancer treatment
4. Saliva proteins could help detection of oral cancer
5. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
6. Breakthrough optical technology to assess colon cancer risk, accuracy
7. Breast cancer cells recycle to escape death by hormonal therapy
8. Nanodiamond drug device could transform cancer treatment
9. Second lumpectomy for breast cancer reduces survival rates
10. Study looks at psychological impact of gene test for breast cancer
11. SNM releases new fact sheet on breast cancer and molecular imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):
(Date:4/19/2017)... Indiana (PRWEB) , ... April 18, 2017 , ... Alisa ... 2017 Distinguished Alumni Awards from the Purdue College of Pharmacy in Lafayette, Indiana. ... Purdue Pharmacy Program for achievements in their careers and other scientific endeavors. , ...
(Date:4/19/2017)... ... 19, 2017 , ... WHO: Peggy Lillis Foundation, the preeminent ... advocacy. Founded in 2010 in memory of a single-parent mom and kindergarten teacher ... the most-consulted source for patient-focused information on C. diff infections in the nation. ...
(Date:4/19/2017)... WESTMINSTER, Colo. , April 19, ... industry-leading specialty finance firm that provides senior debt ... announced the closing of a $20 million senior ... privately-held orthobiologics company engaged in the development and ... treatment of orthopedic injuries. Cerapedics, lead ...
(Date:4/18/2017)... Jordan, Utah (PRWEB) , ... April 18, 2017 ... ... and collaboration company, has been awarded Channel Partners 2017 Next-Gen Solution Provider. , ... create business value for customers with their vision, innovation, and advocacy of the ...
Breaking Biology Technology: